There’s always plenty to talk about in the cannabis space–even more so now that the Canadian government officially unveiled its plans to legalize it by July 1, 2018.
Still–it’s not all buds and roses, at least not right now, as the Federal government’s opposition–the Conservatives and even the NDP–have posed questions regarding some of the legislations the government is seeking.
As reported by the Financial Post, the government is seeking to put in place a marijuana tracking system that will gather information about the product from licensed producers, distributors and retailers. The publication further states that Health Canada said the system won’t track individual cannabis users, but will permit businesses and regulators to trace products and address recalls.
In a statement, Health Canada said specifics of the system still need to be worked out, but that similar ones have been put in place in the US for getting information on marijuana products.
“Mandatory product track-and-trace systems are common features in other jurisdictions that have legalized cannabis for non-medical purposes,” the department said. Health Canada added no cost for the proposed tracking system has been decided on, at least not yet, just the intention that the costs will be offset by licensing and other fees.
This is where the Conservative party is critical–and the NDP.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 


“They want to put a pot registry in, but they are not telling us about how much it is going to cost,” Conservative health critic Colin Carrie was quoted as saying by CTV News. “It is just basically more shady behaviour when it comes to this file.”
Alistair MacGregor, the NDP justice critic, was “surprised” the government hasn’t offered more information.
“On the day this bill was announced, they did bring out the minister of national revenue,” MacGregor was quoted as saying. “One of the biggest questions we have is the cost of implementing not just this registry but all of the enforcement measures; How much of this is going to be downloaded on to the provinces?”
Following the Conservative party and NDP’s critics, a number of cannabis stocks have fluctuated in terms of price: shares of top seed, Canopy Growth (TSX:WEED), have seen a 0 percent increase and remain at $9.87; Aurora Cannabis (TSXV:ACB) are up 1.1 percent to $2.76; Maple Leaf Green World is up 1.69 percent to $0.60, while InvictusMD (TSXV:IMH) is down 2.9 percent to $2.01.
Don’t forget to follow us @INN_Resource for real-time news updates.
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article. 
Editorial Disclosure: Maple Leaf Green World and InvictusMD are clients of the Investing News Network. This article is not paid for content.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less